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ABSTRACT: Development of both potent and selective
kinase inhibitors is a challenging task in modern drug dis-
covery. The innate promiscuity of kinase inhibitors largely
results from ATP-mimetic binding to the kinase hinge region.
We present a novel class of substituted 7,8-dichloro-1-oxo-β-
carbolines based on the distinct structural features of the
alkaloid bauerine C whose kinase inhibitory activity does not
rely on canonical ATP-mimetic hinge interactions. Intrigu-
ingly, cocrystal structures revealed an unexpected inverted
binding mode and the presence of halogen bonds with kinase backbone residues. The compounds exhibit excellent selectivity
over a comprehensive panel of human protein kinases while inhibiting selected kinases such as the oncogenic PIM1 at low
nanomolar concentrations. Together, our biochemical and structural data suggest that this scaffold may serve as a valuable
template for the design and development of specific inhibitors of various kinases including the PIM family of kinases, CLKs,
DAPK3 (ZIPK), BMP2K (BIKE), and others.
■ INTRODUCTION
Major drug discovery efforts for novel targeted therapies of
various human malignancies focus on the human kinome. This
is not surprising because protein kinases, being the largest
family of enzymes in mammals,
1 play pivotal roles in many
cellular processes including proliferation, differentiation, main-
tenance, apoptosis, and human disease. Indeed, modulation of
phosphorylation signaling pathways by small molecules has
demonstrated considerable clinical efficacy in the treatment
of devastating disorders such as cancer. The introduction of
imatinib
2 for the therapy of chronic myelogenous leukemia
(CML) and more recently the use of crizotinib in anaplastic
lymphoma kinase (ALK) dependent tumors
3 constitute mile-
stones in the development of modern therapeutics. However, as
most kinase inhibitors compete with ATP for binding to highly
conserved residues in the enzyme’s active site, achieving potent
inhibition while preserving selectivity is an issue that sub-
stantially contributes to unwanted side effects and thus high
failure rates in drug development programs. Consequently,
non-ATP-mimetic kinase inhibitors that are anchored to more
diverse regions of the ATP binding site may result in more
selective inhibitors.
As natural compounds provide a rich source of bioactive
chemical scaffolds, we recently investigated the total syntheses
of the β-carboline alkaloids bauerines A, B, and C.
4 Bauerine C
(1, Chart 1), isolated from the blue-green alga Dichotrix baueriana,
features a distinct 6,7-dichloroindole substructure and has been
shown to exhibit both antiproliferative and antiviral properties.
5 In
addition, related 1-oxo- β-carbolines such as 2 (Chart 1) have been
reported as RET kinase inhibitors
6 and it has been suggested those
compounds are able to interact with hinge backbone residues in a
canonical way via the pyridone NH and carbonyl, respectively.
Recently, we reported a novel cdc2-like-kinase (CLK) inhibitor,
KH-CB19 (3),
7 which we designed based on the peculiar 6,7-
dichloroindole motif of natural compound 1 (Chart 1). Because of
methylation at the indole nitrogen, 3 is unable to establish classical
hydrogen bond interactions with the hinge backbone. Instead,
cocrystal structures of 3 with CLK3 revealed an unusual, non-ATP
mimetic binding mode. Selectivity screening against a compre-
hensive panel of kinases showed that the inhibitor is highly specific
for CLK kinases, allowing pharmacologic modulation of alternative
Received: September 27, 2011
Published: December 5, 2011
Article
pubs.acs.org/jmc
© 2011 American Chemical Society 403 dx.doi.org/10.1021/jm201286z | J. Med. Chem. 2012, 55, 403−413pre-mRNA splicing. Notably, we found that compound 3 forms an
unusual halogen bond between the 6-chloro substituent and kinase
hinge residues. Although those interactions are considered weak in
comparison to classical hydrogen bonds, they benefit from a lower
desolvation penalty and may very well contribute to inhibitor
specificity.
8 Other well-known examples of carbonyl−halogen
interactions include 4,5,6,7-tetrabromobenzimidazole-based inhib-
itors of CK2.
9 Our observations with our novel inhibitor 3
prompted us to further explore the chemical and biological space
around this scaffold, focusing on diversely functionalized derivatives
of alkaloid 1, e.g., 3-aminobauerine C (4) (Chart 1),
10 and in
particular substitution patterns that will not allow canonical ATP-
mimetic hydrogen bonds with the kinase hinge backbone. We
hypothesized that derivatives of 1 either bearing bulky substituents
at position 3 or genuine tetracyclic spiro analogues will most likely
prevent the classical ATP-mimetic binding mode mediated by the
pyridone NH and carbonyl group. In the course of these efforts we
incidentally discovered a novel synthetic procedure for the pre-
paration of 3-substituted 4-cyano-1,2,3,4-tetrahydro-1-oxo-β-carbo-
lines.
10 Starting from substituted ethyl 3-cyanomethylindole-
2-carboxylates, this approach allows for the convenient synthesis
of highly substituted tricyclic (5−8) and tetracyclic spiro (9−11)
analogues of bauerine C (1) as depicted in Table 1. To enable an
in-depth investigation of SAR, we expanded our initial set of com-
pounds with a variety of structurally modified analogues 16−24.
Herein, we present the activity of this novel class of
compounds as potent and specific inhibitors of a number of
serine/threonine kinases including the disease-related kinases
PIM1
11 and DAPK3. DAPK3, also known as ZIP kinase
(ZIPK) or DAP-like kinase (Dlk), belongs to a family of kinases
that are part of the CAMK group and that have been implicated
in modulation of cell death signaling cascades.
12 Furthermore, it
has been shown that DAPK3 is involved in inflammatory
processes
13 and smooth muscle myosin phosphorylation, which
suggests DAPK3 as an attractive target for related disorders
such as hypertension and asthma.
14 Cocrystal structures of
optimized compounds with PIM1 and DAPK3 (ZIPK) revealed
an ATP-competitive but not ATP-mimetic binding mode that
lacks classical hydrogen bond interactions with the kinase hinge
backbone. Instead the chlorine atoms are oriented toward the
hinge region and, similar to our CLK inhibitor 3, form in some
cases halogen bonds with backbone carbonyls. Because of their
distinct binding modes, the screened inhibitors showed a
limited number of cross reactivities with other kinases over a
comprehensive kinase selectivity panel. Furthermore, selected
compounds display interesting differential kinase affinities,
indicating that this scaffold may represent a versatile design
template for the development of novel BMP2K (BIKE), CLK,
and DRAK1 inhibitors which might find clinical applications
outside the oncology target area.
■ RESULTS AND DISCUSSION
Chemistry. Alkaloid 1 was prepared starting from diaz-
otated 2,3-dichloroaniline and 3-(ethoxycarbonyl)piperi-
done using a Japp−Klingemann reaction as the crucial step as
described in ref 4. The initial set of 1-oxo-β-carbolines
including 4 and compounds 5−11 (Table 1) was synthesized
by reaction of substituted ethyl 3-cyanomethyl-1H-indole-2-
carboxylates such as 12 with gaseous ammonia/ammonium
chloride and the corresponding ketones following our
previously reported procedure.
10 On the basis of our hypothesis
discussed above, four sections of the core scaffold were selected
for further modifications in order to establish SAR: (i) the
pyridone ring of natural compound 1, (ii) the spirocycle
attached to position 3, (iii) the 9-methyl substituent at the
indole nitrogen, and (iv) the nitrile group at position 4.
For the preparation of 3-azabauerine C (16)i nw h i c ht h e
pyridone ring of alkaloid 1 is replaced by a pyridazinone, ethyl
Chart 1. Bauerine C (1), 1-Oxo-β-carboline RET Inhibitor
(2), CLK Inhibitor (3), and 3-Aminobauerine C (4)
Table 1. Initial Set of 1-Oxo-β-carbolines
compd R1 R2 R3 compd R X n
5 Cl CH3 CH3 9 CH3 CH2 2
6 Cl H CH3 10 CH3 CH2 1
7 Cl CH3 CH2CH3 11 CH3 O2
8 HC H 3 CH3
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10 was alkylated with methyl
iodide in DMF after deprotonation with sodium hydride to give N-
methylated indole 14 (Scheme 1A). Formylation of 14 using
Vilsmeier conditions afforded carbaldehyde 15 which was cyclized
with hydrazine, yielding 3-azabauerine C (16).
To elucidate the effect of heteroatoms within the saturated
spiro ring at C-3 of the β-carboline core, nitrogen-containing
N-methyl- and N-ethyl-spiropiperidine derivatives 17 and 18
were prepared in the known manner
10 using 12 and appropriate
N-alkyl-4-piperidone building blocks (Scheme 1B). Synthesis of N-
unsubstituted analogue 20 was achieved via the N-Boc-protected
intermediate 19 by cyclization of 12 with N-Boc-4-piperidone,
followed by mild deprotection with TFA in dichloromethane.
15 We
decided to use the N-Boc-protected intermediate, as the Boc group
should be stable toward the strong basic conditions applied during
the cyclization step. Furthermore the intermediate was considered
to be of possible interest for SAR because of the bulky substituent
at the piperidine nitrogen. In order to address the importance of
the 9-methyl substituent in the tetracyclic spiro series, 22 was
prepared from 21 and cyclohexanone using our general procedure
(Scheme 2A). By employment of triethylbenzylammonium
chloride (TEBAC) mediated phase-transfer catalysis,
16 22 can be
alkylated with dimethyl sulfate and potassium carbonate in
acetonitrile, yielding 9-methyl derivative 9. This protocol allows
for the selective alkylation of the indole nitrogen without affecting
the lactam nitrogen and constitutes a feasible alternative to our
previously reported procedure for selective N-methylation of 1-oxo-
β-carbolines.
4 To determine the importance of the cyano group at
position 4, we chose to prepare primary amine 23 from our original
lead compound 5. The reduction of nitriles in the presence of
amides is usually quite challenging, since both carbon atoms are at
the same oxidation level. Furthermore, in the case of 5, catalytic
hydrogenation using Raney nickel, palladium, or platinum on
carbon catalysts is not promising because these methods bear the
risk of removing halogen substituents from aromatic rings.
17 Initial
attempts using sodium borohydride in combination with cobalt or
nickel salts
18 were unsuccessful, yet we were able to selectively
reduce the cyano group of 5 with tetra-N-butylammonium boro-
hydride (Scheme 2B).
19 Finally, amine 23 was acetylated with
acetic anhydride in toluene to give acetamide 24.
Selectivity of 7,8-Dichloro-1-oxo-β-carbolines. All
compounds including alkaloid 1 were screened against a kinase
panel using a thermal stability shift assay.
20 This assay depicts a fast
and reliable method to determine a ligand affinity ranking, and the
obtained results correlate well with previously published kinetic
data.
7,20 Kinase target hits for active compounds are summarized in
Table 2, applying a Tm shift value of 4.0 °C as cutoff (for complete
Tm shift screening results, see Table S1 in Supporting
Scheme 1. (A) Synthesis of 3-Azabauerine C (16)
a and (B) Synthesis of Spiropiperidines 17−20
b
aReagents and conditions for part A: (i) NaH, DMF, 40 °C, 1 h, then CH3I, room temp, 5 h; (ii) POCl3, DMF, room temp, 40 min, then 60 °C, 4 h;
(iii) hydrazine, 1,4-dioxane, reflux, 3 h. Percentages given correspond to relative yields.
bReagents and conditions for part B: (i) NH3,N H 4Cl,
100 °C, 1 h, sealed tube; (ii) TFA, CH2Cl2, room temp, 35 min. Percentages given correspond to relative yields.
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kinome tree revealed a distinct and specific pattern of kinase targets
(Figure 1). Overall we found that compounds bearing a
spiropiperidine moiety such as 17, 18,a n d20 are highly potent
inhibitors of PIM1/3 and DAPK3, whereas bauerine C (1)a n d
derivatives 4 and 16 as well as primary amine 23 exhibited exciting
activities against so far largely unexplored kinases such as BMP2K
and DRAK1.
From investigation of the SAR around parent compound 1 a
bit more closely and with particular regard to PIM kinases,
the Tm shift assay revealed 3,3-dimethyl derivative 5 and
3-aminobauerine C (4) to exert reasonable affinity toward
PIM1, both superior to bauerine C (1) (Table S1, Supporting
Information). Notably, compound 6, which does not have a
methyl substituent at the indole nitrogen, and the halogen-free
analogue 8 showed significantly reduced activity against PIM1
in comparison to 5, suggesting beneficial effects of both the
9-methyl and 7,8-dichloro substituents. Prolongation of alkyl
chains at position 3 as in 7 also led to weaker binding, whereas
among the initial group of spiro compounds 9, 10, and 11,
expansion of ring size and introduction of heteroatoms to the
saturated spirocarbocycle seemed to favor activity. Remarkably,
removal of the 9-methyl group in the spirocyclohexyl series as
in 22 compared to 9 did not result in such a dramatic loss in
activity as observed for the tricyclic compounds (5 vs 6),
probably indicating a different mode of binding. Reduction of
the nitrile group at C-4 again led to a slight decrease in affinity
for primary amine 23 in comparison to lead compound 5 with
regard to PIM1. N-Acetylation of amine 23 to give acetamide
24 resulted in complete loss of activity. Strikingly, investigation
of the newly prepared spiropiperidine compounds revealed 17,
18, and 20 as highly potent inhibitors of PIM1 kinase. The top
compound in this series was found to be 20, which is not
substituted at the spiropiperidine nitrogen. Introduction of an
N-methyl substituent as in 17 was well-tolerated; however, an
N-ethyl group as in 18 resulted in marginally diminished
activity. Notably, N-Boc-protected intermediate 19 did not
exhibit any inhibitory potency.
To further examine the selectivity of the newly identified
inhibitors, kinase profiling using the thermal shift assay was
extended for up to more than 100 kinases (Table S1,
Supporting Information). For 20, we observed temperature
shifts of >8 °C only for PIM1, PIM3, and DAPK3, emphasizing
that compound 20 not only is a highly potent inhibitor of the
PIM family of kinases but also displays good selectivity. Among
the PIM kinase family, Tm shift data showed a significant lower
Tm shift for PIM2, suggesting lower activity of 20 on this
target. Similar selectivity patterns were detected for N-methyl-
and N-ethylspiropiperidine derivatives 17 and 18, yet these
were slightly less potent against all three PIM kinases and
inhibition of DAPK3 was significantly reduced. In general, both
tri- and tetracyclic compounds exhibited a comparable trend in
activity for PIM1 and CLK1, yet the spiropiperidines 17, 18,
and 20 did give considerably higher Tm shift values for PIM1
compared to CLK1. Among the other compounds, especially 5
and 3-aminobauerine C (4) demonstrated reasonable activity
against PIM1.
Interestingly, only parent alkaloid 1 and its closely related
derivatives 4 and 16 as well as 5 inhibited TGFβ receptor
kinase (TGFBR2) with good potency. We also observed
moderate activity for 1, 4, and 5 against DRAK1, whereas 3-
azabauerine C (16) seems to be quite selective for TGFBR2.
However, the most potent compound with regard to DRAK1
was found to be primary amine 23. It is noteworthy that among
all evaluated compounds only bauerine C (1) gave a Tm shift
of >8 °C for BMP2K.
Scheme 2. (A) Preparation of 9-Methyl Analogue 9 via Selective N-Alkylation of 22
a and (B) Synthesis of Primary Amine
23 and Acetamide 24
b
aReagents and conditions for part A: (i) cyclohexanone, NH3,N H 4Cl, 100 °C, 1 h, sealed tube; (ii) TEBAC, K2CO3,C H 3CN, room temp, 15 min,
then 22 and (CH3O)2SO2, room temp, 12 h. Percentages given correspond to relative yields.
bReagents and conditions for part B: (i) Bu4NBH4,
CH2Cl2, reflux, 24 h; (ii) Ac2O, toluene, 80 °C, 1 h. Percentages given correspond to relative yields.
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assay, we also determined IC50 values for our most potent
compound 20. In a kinetic enzyme assay using 100 μM ATP,
we determined IC50 values of 60 and 90 nM for PIM1 and
PIM3, respectively (data not shown). To further corroborate
the data obtained in the Tm shift assay, we also screened our
top inhibitor 20 against a comprehensive kinase selectivity
panel (Table 3). In general, the kinetic data correlated well with
the results from the Tm shift assay, although we identified
CAMK2 and PKA as additional targets that were inhibited by
20 with IC50 values below 100 nM. This may be related to the
activation state of these two kinases, since inactive enzymes
were used for Tm screening. In summary, the main cross-
reactivities of compound 20 are within the AGC family, in
particular with PKA, ROCK, and PKN1/2. Outside the AGC
family we observed cross-reactivity with CK1 and CaMK2
(Figure 1). However, in contrast to the clinically evaluated
imidazo[1,2-b]pyridazine-based PIM inhibitor SGI-1776,
21
compounds 17 and 20 did not exhibit any significant activity
against PDGFRα, FLT3, or KIT.
Binding Mode. To gain insights on the binding mode and
thus be able to rationalize SAR, we first determined the crystal
structures of 17 and 20 in complex with PIM1 (PDB codes
3CXW and 3CY2) (Figure 2A and Supporting Information
Figure S1). The structures revealed that both inhibitors do not
establish any classical hydrogen bond interactions with the
hinge region. Interestingly, the lactam moiety does not
contribute to inhibitor binding, as the hydrophobic dichloro-
benzene ring is oriented toward the hinge while the pyridone
and spiropiperidine rings are pointing toward the back of the
binding pocket. This allows formation of bidentate H-bonds
between the spiropiperidine nitrogen and Asn172 as well as
Asp186. The observed binding mode for 17 and 20 is therefore
in contrast to the one described for other 1-oxo-β-carbolines
reported as CDK2 or RET inhibitors.
6,22 As shown in Figure 3,
compounds that are not substituted at positions 3 and 4 are
likely to establish classical, ATP-mimetic interactions between
the pyridone ring and kinase hinge backbone residues. These
can be mediated via formation of a hydrogen bond between the
inhibitor’s lactam carbonyl and the backbone NH of Leu83
(CDK2 numbering) and a second one between the pyridone-
NH and Glu81 (Figure 3A). Alternatively, all interactions can
be established between the pyridone moiety and Leu83
exclusively (Figure 3B). However, either of those binding
modes is incompatible with 17 and 20, probably because of the
bulky nature of the spiro ring which prevents the novel
inhibitors from assuming an ATP-mimetic orientation.
Table 2. Kinase Targets with ΔTm > 4 °C
a
aSee Table S1 (Supporting Information) for complete thermal shift assay data. Values are shown in °C. Empty spaces indicate that no data have been
measured. Targets with significant Tm shift have been colored in red (>8 °C) and yellow (>4 °C), respectively.
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that the cyano group is not involved in a hydrogen bond
interaction with Lys67, which is in contrast to comparably
substituted 3-cyanopyridones reported as PIM inhibitors by
Cheney et al. (PDB code 2OBJ).
23 Various other PIM inhibitor
scaffolds, e.g., pyrrolo[2,3-a]carbazoles
24 and 3H-benzo[4,5]-
thieno[3,2-d]pyrimidin-4-ones,
25 also form hydrogen bonds
with this highly conserved residue. The DFG motif assumes an
active “in” conformation, and two hydrophobic residues, the
gatekeeper Leu120 and the DFG-adjacent Ile185, enclose the
tricyclic core ring system (not shown). As in several other
reported PIM inhibitor complexes,
20,24,26−28 17 and 20 also
induce a conformational change in the glycine-rich P-loop by
which Phe49 flips into the active site (not shown). This
structural rearrangement on the one hand enables additional
stacking effects with the inhibitor but also shifts the kinase in an
inactive conformation which is incompatible with substrate
binding. Regarding the difference in activity observed for
different PIM isoforms, despite the high sequence homology
among all three isoforms, kinetic studies suggest that ATP KM
values for PIM1/PIM3 and PIM2 differ remarkably.
29 This may
explain the so far unsuccessful efforts to target all three kinases
with an ATP-competitive inhibitor. PIM2 has a leucine residue
instead of glutamate at position 124 in the hinge region, which
disrupts the polar interactions with Arg122 observed in PIM1.
30
As a result, the arginine side chain is disordered, which in com-
bination with another amino acid change (Val126Ala) might
influence hinge dynamics and hence inhibitor binding due to
reduced availability of hydrophobic interactions and higher
desolvation energy.
25 In PIM3 the glutamate residue at position
124 is conserved but like PIM2 Val126 is replaced by alanine which
may cause slightly weaker binding of the inhibitors.
Interestingly, the DAPK3 cocrystal structure with 17 (PDB
code 3BHY) revealed a different mode of binding compared to
the PIM1 structure (Figure 2B). In the DAPK3 complex, the
inhibitor’s lactam carbonyl establishes a hydrogen bond with a
water molecule in the active site which itself is involved in a
hydrogen bond network with Ser21 (not shown). The
spiropiperidine ring appears a little more twisted compared to
the PIM1 structure (Figure 2C) and does not seem to
participate in any polar interactions. However, the electron
density for the piperidine in the obtained cocrystal structure
Figure 1. Kinome tree visualization of inhibitor selectivity for compound 20
combining both Tm shift and kinetic assay results (illustration reproduced
courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).
Table 3. In Vitro Kinase IC50 Values Determined for
Compound 20
target
IC50
(μM) target
IC50
(μM) target
IC50
(μM)
ALK >10 HCK >10 PKBα >10
AURORA A >10 HER1 >10 PKCα 2.2
AXL >10 HER2 >10 PKCθ 1.4
BTKv2 >10 HER4 >10 PKN1 0.31
cABL >10 IGF1R >10 PKN2 0.30
cABLT315I >10 Ins1R >10 PLK1 >10
CaMK2 0.083 IRAK4 >10 RET 7.7
CDK2 >10 JAK1 >10 ROCK2 0.22
CDK4/D1 >10 JAK2 >10 RON >10
CK1α 0.33 JAK3 >10 S6K 0.23
cKIT >10 KDR 7.2 SYK >10
cMET >10 LCK >10 TYK2 >10
COT1 >10 LYN >10 VPS34 >9.1
CSK >10 MK2 >10 WNK1 >10
cSRC >10 MK5 1.7 YES >10
EphA4 >10 mTOR >9.1 ZAP70 >10
EphB4 >10 p38α >10 PKA 0.077
ERK2 >10 PAK2 >10 GSK3β >10
FAK >10 PDGFRa >10 PIM2 0.24
FGFR-1 >10 PDK1v2 >10 FYN >10
FGFR-2 >10 PI3Kα >9.1 FLT3 >10
FGFR-3 >10 PI3Kβ 8.6 PI4Kβ 2.5
FGFR3K >10 PI3Kδ 4.7 PI3Kγ 3.1
FGFR-4 >10
Figure 2. (A) Crystal structure of 17 bound to PIM1 (PDB code
3CXW). Hydrogen bonds are depicted as yellow dots. (B) Cocrystal
structure of 17 in complex with human DAPK3 (PDB code 3BHY).
(C) Comparison of electron density maps of 17 bound to PIM1 (top)
or DAPK3 (bottom), respectively. (D) Superimposition of hinge areas
of PIM1 and DAPK3 structures with bound inhibitor 17. Halogen
bonds are shown as green dots.
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moiety. Similar to PIM1, 17 benefits from hydrophobic
interactions with the gatekeeper (Leu93) and an isoleucine
(Ile160) residue N-frontal to the DFG motif (not shown).
More interestingly, in this structure we observed establishment
of halogen bonds between the 7,8-dichloro substituents of 17
and the backbone carbonyl of Glu94 and Val96, respectively
(Figure 2D), similar to the interactions we had discovered for
our recently reported novel CLK inhibitor 3 (PDB code
2VAG).
7 The expanded nature of the hinge region in PIM1 due
to insertion of two proline residues (Pro123 and Pro125)
prohibits formation of such a halogen bond as illustrated in
Figure 2D.
31 In the DAPK3 complex the halogen in position 8
was partially radiolyzed. Additional electron density observed in
the vicinity of the 7,8-dichloro substituents was interpreted as a
chloride ion with partial occupancy. We also observed complete
radiolysis of the C−Cl bond at this position in the data set
collected on the PIM1 complex with 20 (PDB code 3CY2,
Supporting Information Figure S1).
Cellular Assays. As aberrant expression of PIM kinases
has been observed for numerous types of cancer, e.g., leuke-
mia,
32−34 lymphoma,
35,36 and solid tumors such as prostate,
37,38
colon,
39 and pancreatic
40 cancer, we evaluated the antiprolifer-
ative potential of our most potent inhibitor 20 and its effects on
PIM downstream signaling. For this purpose, 20 was screened
against five human leukemia cell lines and IC50 values were
determined after 48 h of treatment, showing low micromolar
potency comparable to data previously reported for imidazo-
[1,2-b]pyridazine PIM inhibitors (Table 4).
41 However,
consistent with our observation that 20 is selective for PIM1
with regard to FLT3 in contrast to imidazo[1,2-b]pyridazine-
based PIM inhibitors, cytotoxic activity for cell lines harboring
the FLT3-ITD mutation such as MV4;11 and MOLM13 was
reduced. To further confirm the biological activity of our lead
compound, we also tested 20 for its ability to inhibit
phosphorylation of a known PIM downstream target. Using
the human MV4;11 acute myeloid leukemia (AML) cell line,
we found a dose-dependent decrease in phosphorylation of 4E-
BP1
11 as a result of PIM inhibition by 20 (Figure 4).
■ CONCLUSION
In this study we present substituted 7,8-dichloro-1-oxo-β-
carbolines as a novel and versatile scaffold for the development
of non-ATP-mimetic kinase inhibitors. SARs around the core
scaffold which we derived from the natural compound bauerine
C( 1) were established, and optimized compounds of the 4-
cyano-1,2,3,4-tetrahydro-1-oxo-β-carboline type such as the
spiropiperidine 20 are highly potent inhibitors of the oncogenic
PIM kinases and DAPK3 (ZIPK). Because of their unusual
binding mode revealed by X-ray crystallography, the inhibitors
display good specificity among a comprehensive kinase
selectivity panel with only a few off-targets within and outside
the AGC family. Upon binding to PIM1 the inhibitors induce a
Figure 3. Canonical binding mode of 1,2,3,4-tetrahydro-1-oxo-β-carbolines docked into human CDK2. In contrast to the spirocyclic compound 17
(Figure 2) main interactions are mediated between the inhibitor’s lactam ring and kinase hinge backbone residues Glu81 and Leu83 (A) or Leu83
exclusively (B).
Figure 4. MV4;11 cells were incubated with increasing concentrations
of 20 for indicated times and harvested, and protein extracts were
separated by SDS−PAGE. The effect of 20 on the PIM endogenous
target 4E-BP1 was followed by Western blotting with the indicated
phosphospecific antibody. Membranes were stripped and reprobed
with nonphosphospecific and anti-actin antibodies to check for equal
loading.
Table 4. Comparison of Cellular IC50 Values Determined for
Compound 20 and an Imidazo[1,2-b]pyridazine-Based
Inhibitor
IC50 (μM)
a
cell line 20
K00135
(imidazo[1,2-b]pyridazine-type
inhibitor)
MV4;11 (MLL, FLT3-ITD-
positive)
2.07 0.4
RS4;11 (ALL) 3.57 8.8
MOLM13 (AML, FLT3-ITD-
positive)
3.25 0.3
SEM (ALL) 4.68 6
K562 (CML, blast crisis) 6.49 8
aDeterminations were done after 48 h of preincubation. K00135 values
are adopted from ref 41.
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into an inactive state. The novel compounds also exhibit
efficacy in cellular assays, as 20 was found to deplete PIM-
dependent phosphorylation of downstream effector proteins
and demonstrated antiproliferative activity at low micromolar
concentrations in related cell viability screens. Importantly, we
found an intriguing binding mode for the N-methyl analogue
17 in complex with DAPK3 which revealed formation of
halogen bonds with the kinase hinge region. These interactions
may contribute to inhibitor selectivity and further underscore
the interesting features and versatility of our 6,7-dichloroindole
scaffold. Because of active site similarities, this novel class of
compounds may also serve well as template for the preparation
of new CLK inhibitors.
7 Moreover, activities observed for some
of the other analogues presented herein indicate that selected
compounds such as alkaloid 1 and primary amine 23 could also
be optimized for the development of new targeted inhibitors of
BMP2K (BIKE) and DRAK1. Consequently, efforts to further
improve potency and selectivity of those compounds are under way.
■ EXPERIMENTAL SECTION
General Information. NMR spectra were recorded on a JEOL
JNMR-GSX 400 and a JEOL JNMR-GSX 500 (JEOL, Peabody, MA,
U.S.), using TMS as internal standard. Chemical shifts are given in
ppm, and coupling constants are given in hertz. The spectra were
recorded at room temperature, unless stated otherwise. Mass spectra
(electronic ionization, EI, 70 eV) were recorded using a Hewlett-
Packard 5989 A mass spectrometer with a 59980 B particle beam LC/
MS interface (Agilent Technologies, Palo Alto, CA, U.S.). IR spectra
were recorded as KBr disks on a Perkin-Elmer FT-IR Paragon 1000
(Perkin-Elmer, Waltham, MA, U.S.) or JASCO FT/IR-410 (JASCO,
Easton, MD, U.S.). Melting points were determined with a Büchi B-
540 apparatus (Büchi, Flawil, Switzerland) and are uncorrected. Elemental
analyses were performed using a CHN-Elementaranalysator Rapid
(Heraeus, Hanau, Germany) or Elementaranalysator VarioE L( E l e m e n t a r ,
Hanau, Germany). Purification by flash column chromatography (FCC)
was done using silica gel 60 (Merck, Darmstadt, Germany). The purity of
the synthesized compounds was determined and confirmed by combustion
analysis.
All chemicals were purchased from Sigma-Aldrich, Fluka, and Acros
and used without further purification.
Bauerine C (1) was prepared as reported previously,
4 and procedures
and spectral data for compounds 4−12 and 21 are provided in ref 10. For
procedures and experimental data for compounds 14 and 15 as well as
general additional spectroscopic data see Supporting Information.
6,7-Dichloro-5-methyl-3H-pyridazino[4,5-b]indol-4(5H)-one
Hemihydrate (16). Compound 15 (474 mg, 1.6 mmol) and hydra-
zine hydrate (192 mg, 4.8 mmol) were dissolved in 1,4-dioxane
(50 mL), and the mixture was heated to reflux for 3 h. After the
mixture was cooled, the crude precipitated product was filtered off and
recrystallized from ethyl acetate to give 241 mg (56%) of 16 as a
yellow solid. Mp 307 °C; 1H NMR (400 MHz, DMSO-d6) δ 12.96
(br s, 1 H, N−H), 8.78 (s, 1 H, 1-H), 8.19 (d, J = 8.5 Hz, 1 H, 9-H),
7.56 (d, J = 8.5 Hz, 1 H, 8-H), 4.63 (s, 3 H, N−CH3); MS EI m/z
(relative intensity, %) 270 [M+￿ + 4] (14), 268 [M+￿ + 2] (67), 266
[M+￿] (100). Anal. (C11H7Cl2N3O·0.5H2O) C, H, N.
General Procedure for Preparation of Spiro-4-cyano-1-oxo-
β-carbolines. Synthesis of compounds 17−19 and 22 was achieved
by using the previously reported procedure.
10 Briefly, the appropriate ethyl
3-(cyanomethyl)indole-2-carboxylate (12 or 21, 3.21 mmol) and
ammonium chloride (6.42 mmol) were suspended in the given amount
of ketone in a glass tube. After the mixture was cooled to −80 °C, gaseous
ammonia was introduced into the tube until an amount of ∼10 mL was
condensed. The tube was closed tightly and heated to 100 °Cf o r1 6hi n
an autoclave. The mixture was allowed to reach room temperature and
after evaporation of excess ammonia extracted with ethyl acetate (3 ×
30 mL). The combined organic layers were dried over sodium sulfate,
filtered, and the solvent was removed. The crude product was purified
by flash column chromatography.
(4′RS)-7′,8′-Dichloro-1,9′-dimethyl-1′-oxo-1′,2′,4′,9′-
tetrahydrospiro[piperidine-4,3′-pyrido[3,4-b]indole]-4′-car-
bonitrile (17). 17 was prepared from 12 (1.00 g, 3.21 mmol) and N-
methyl-4-piperidone (5 mL) following the general procedure for
preparation of spiro 4-cyano-1-oxo-β-carbolines. Eluent for FCC was
dichloromethane/ethanol (3:1). The crude product was recrystallized
from ethanol to give 568 mg (47%) of 17 as pale pink crystals. Mp 284
°C; 1H NMR (400 MHz, DMSO-d6,5 0°C) δ 8.12 (br s, 1 H, N−H),
7.88 (d, J = 8.6 Hz, 1 H, 5′-H), 7.43 (d, J = 8.6 Hz, 1 H, 6′-H), 4.97
(s, 1 H, 4′-H), 4.46 (s, 3 H, 9′-CH3), 2.66 (m, 1 H, 2-/6-H), 2.47 (m,
1 H, 2-/6-H), 2.33 (br t, J = 5.5 Hz, 2 H, 2-/6-H), 2.22 (s, 3 H, 1-CH3),
2.06 (m, 1 H, 3-/5-H), 1.97 (m, 1 H, 3-/5-H), 1.70 (br t, J = 5.5 Hz,
2H ,3 - / 5 - H ) ;M SE Im/z (relative intensity, %) 380 [M+￿ +4 ]( 8 ) ,3 7 8
[M+￿ + 2] (35), 376 [M+￿] (53), 317 (100), 236 (30), 195 (23). Anal.
(C18H18Cl2N4O) C, H, N.
(4′RS)-7′,8′-Dichloro-1-ethyl-9′-methyl-1′-oxo-1′,2′,4′,9′-
tetrahydrospiro[piperidine-4,3′-pyrido[3,4-b]indole]-4′-car-
bonitrile (18). 18 was prepared from 12 (1.00 g, 3.21 mmol) and N-
ethyl-4-piperidone (5 mL) following the general procedure for
preparation of spiro 4-cyano-1-oxo-β-carbolines. Eluent for FCC was
dichloromethane/ethanol (5:1). The crude product was recrystallized
from ethanol to give 914 mg (73%) of 18 as white crystals. Mp
276 °C; 1H NMR (500 MHz, DMSO-d6,5 0°C) δ 8.15 (br s, 1 H,
N−H), 7.89 (d, J = 8.5 Hz, 1 H, 5′-H), 7.43 (d, J = 8.5 Hz, 1 H, 6′-H),
4.97 (s, 1 H, 4′-H), 4.46 (s, 3 H, 9′-CH3), 2.70 (m, 1 H, 2-/6-H), 2.48
(m, 1 H, 2-/6-H), 2.38 (q, J = 7.1 Hz, 2 H, CH2CH3), 2.36 (br t, J =
5.5 Hz, 2 H, 2-/6-H), 2.05 (m, 1 H, 3-/5-H), 1.97 (m, 1 H, 3-/5-H),
1.70 (br t, J = 5.5 Hz, 2 H, 3-/5-H), 1.00 (t, J = 7.1 Hz, 3 H, CH2CH3);
MS EI m/z (relative intensity, %) 394 [M+￿ + 4] (8), 392 [M+￿ +2 ]
(44), 390 [M+￿] (69), 375 (18), 317 (100), 236 (21), 195 (20). Anal.
(C19H20Cl2N4O) C, H, N.
(4′RS)-tert-Butyl 7′,8′-Dichloro-4′-cyano-9′-methyl-1′-oxo-
1′,2′,4′,9′-tetrahydrospiro[piperidine-4,3′-pyrido[3,4-b]-
indole]-1-carboxylate (19). 19 was prepared from 12 (1.00 g, 3.21
mmol) and N-Boc-4-piperidone (4.50 g, 22.58 mmol) following the
general procedure for preparation of spiro-4-cyano-1-oxo-β-carbolines.
Eluent for FCC was petroleum ether/ethyl acetate (1:1). The crude
product was recrystallized from ethanol to give 722 mg (49%) of 19 as
white crystals. Mp 250 °C; 1H NMR (500 MHz, CDCl3,5 0°C) δ 7.58
(d, J =8 . 5H z ,1H ,5 ′-H), 7.31 (d, J = 8.5 Hz, 1 H, 6′-H), 6.28 (br s, 1 H,
N−H ) ,4 . 5 5( s ,3H ,9 ′-CH3), 4.15 (s, 1 H, 4′-H), 3.95 (d, J =1 4 . 3H z ,
1H ,2 - / 6 - H ) ,3 . 8 3( d ,J =1 4 . 0H z ,1H ,2 - / 6 - H ) ,3 . 3 2( d d ,J =1 2 . 0H z ,
2.5 Hz, 1 H, 2-/6-H), 3.23 (dd, J =1 1 . 8H z ,2 . 0H z ,1H ,2 - / 6 - H ) ,2 . 1 5−
2.02 (m, 2 H, 3-/5-H), 1.91 (d, J =1 4 . 0H z ,1H ,3 - / 5 - H ) ,1 . 8 1( d d ,J =
12.0 Hz, 2.5 Hz, 2 H, 3-/5-H), 1.47 (s, 9 H, C (CH3)3); MS EI m/z
(relative intensity, %) 466 [M+￿ + 4] (2), 464 [M+￿ +2 ]( 1 4 ) ,4 6 2[ M +￿]
(20), 389 (31), 362 (75), 333 (32), 317 (100), 305 (88), 264 (59), 236
(54), 195 (35). Anal. (C22H24Cl2N4O3)C ,H ,N .
(4′RS)-7′,8′-Dichloro-9′-methyl-1′-oxo-1′,2′,4′,9′-
tetrahydrospiro[piperidine-4,3′-pyrido[3,4-b]indole]-4′-car-
bonitrile (20). To a solution of 19 (270 mg, 0.58 mmol) in
dichloromethane (30 mL) was added trifluoroacetic acid (7.5 mL),
and the mixture was stirred at room temperature for 35 min. The
volatile compounds were removed by azeotropic rotary evaporation
with toluene (10 mL), and the residue was resuspended in 2 M NaOH
solution (10 mL). After extraction with ethyl acetate (3 × 10 mL), the
combined organic layers were dried over MgSO4 and the solvent was
evaporated. The crude product was recrystallized from ethanol to give
124 mg (59%) of 20 as white crystals. Mp 289 °C; 1H NMR (500
MHz, DMSO-d6) δ 8.32 (br s, 1 H, N−H), 7.91 (d, J = 8.5 Hz, 1 H,
5′-H), 7.44 (d, J = 8.5 Hz, 1 H, 6′-H), 5.08 (s, 1 H, 4′-H), 4.46 (s, 3 H,
9′-CH3), 2.99 (m, 1 H, 2-/6-H), 2.78 (m, 1 H, 2-/6-H), 2.64 (m, 2 H,
2-/6-H), 2.23 (br s, 1 H, 1-H), 1.89 (m, 2 H, 3-/5-H), 1.59 (m, 2 H,
3-/5-H); MS EI m/z (relative intensity, %) 366 [M+￿ + 4] (4), 364
[M+￿ + 2] (22), 362 [M+￿] (36), 317 (39), 305 (100), 236 (48), 195
(25). Anal. (C17H16Cl2N4O) C, H, N.
(4′RS)-7′,8′-Dichloro-1′-oxo-1′,2′,4′,9′-tetrahydrospiro-
[cyclohexane-1,3′-pyrido[3,4-b]indole]-4′-carbonitrile (22). 22
was prepared from 21
10 (1.00 g, 3.21 mmol) and cyclohexanone
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cyano-1-oxo-β-carbolines. Eluent for FCC was petroleum ether/ethyl
acetate (1:1). The crude product was recrystallized from ethanol to
give 220 mg (19%) of 22 as white crystals. Mp 281 °C; 1H NMR (400
MHz, DMSO-d6) δ 12.71 (br s, 1 H, 9′-H), 8.17 (br s, 1 H, 2′-H), 7.87
(d, J = 8.3 Hz, 1 H, 5′-H), 7.41 (d, J = 8.3 Hz, 1 H, 6′-H), 5.06 (s, 1 H,
4′-H), 1.95−1.35 (m, 10 H, 2-/3-/4-/5-/6-H); MS EI m/z (relative
intensity, %) 351 [M+￿ + 4] (16), 349 [M+￿ + 2] (62), 347 [M+￿]
(100), 222 (34), 195 (43). Anal. (C17H15Cl2N3O) C, H, N.
(4′RS)-7′,8′-Dichloro-9′-methyl-1′-oxo-1′,2′,4′,9′-
tetrahydrospiro[cyclohexane-1,3′-pyrido[3,4-b]indole]-4′-car-
bonitrile (9). Triethylbenzylammonium chloride (TEBAC; 200 mg,
0.877 mmol) and K2CO3 (138 mg, 1.00 mmol) were suspended in
acetonitrile (30 mL), and the mixture was stirred for 15 min at room
temperature. A solution of 22 (348 mg, 1.00 mmol) in acetonitrile
(20 mL) was added, followed by slow addition of dimethyl sulfate
(126 mg, 1.00 mmol), and the mixture was stirred at room temperature
for 12 h. The solvent was removed by evaporation. The residue was
redissolved in ethyl acetate (50 mL), and the mixture was washed with
water (2 × 20 mL) and brine (2 × 20 mL). The aqueous layer was
reextracted with ethyl acetate (20 mL). The combined organic layers
were dried over MgSO4, and the solvent was evaporated. The crude
product was recrystallized from ethanol to give 202 mg (56%) of 9 as
white crystals. Mp 290 °C. The spectral data were in full accordance
with previously reported values.
10 Anal. (C18H17Cl2N3O) C, H, N.
(4RS)-4-Aminomethyl-7,8-dichloro-3,3-dimethyl-2,3,4,9-tet-
rahydro-1H-pyrido[3,4-b]indol-1-one (23). Tetra-N-butylammonium
borohydride (2.40 g, 9.31 mmol) and 5 (1.00 g, 3.10 mmol) were dissolved
in dichloromethane (100 mL), and the mixture was refluxed for 24 h. After
the mixture was cooled, the solvent was evaporated and the residue
carefully resuspended in 2 M HCl solution (20 mL) followed by refluxing
for 30 min. The mixture was poured onto ice, basified with 2 M NaOH,
and extracted with ethyl acetate (3 × 10 mL). The combined organic layers
were dried over MgSO4, and the solvent was evaporated. The crude
product was purified by FCC (eluent, dichloromethane/ethanol (5:1)).
The product was recrystallized from toluene to give 400 mg (40%) of 23 as
white needles. Mp 202 °C; 1H NMR (400 MHz, CD2Cl2-d2) δ 7.54 (d, J =
8 . 5H z ,1H ,5 - H ) ,7 . 2 1( d ,J = 8.5 Hz, 1 H, 6-H), 5.47 (br s, 1 H, 2-H),
4.53 (s, 3 H, N−CH3), 3.08 (dd, J =1 7 . 3H z ,8 . 0H z ,1H ,C H 2), 2.94 (dd,
J = 17.3 Hz, 8.0 Hz, 1 H, CH2), 2.93 (t, J = 8.0 Hz, 1 H, 4-H), 1.42 (s, 3 H,
3-CH3), 1.29 (s, 3 H, 3-CH3), 1.13 (s, 2 H, NH2); MS EI m/z (relative
intensity, %) 329 [M+￿ + 4] (1), 327 [M+￿ + 2] (4), 325 [M+￿] (6), 296
(44), 281 (100). Anal. (C15H17Cl2N3O) C, H, N.
(4RS)-N-[(7,8-Dichloro-3,3-dimethyl-1-oxo-2,3,4,9-tetrahy-
dro-1H-pyrido[3,4-b]indol-4-yl)methyl]acetamide (24). To a
solution of 23 (388 mg, 1.19 mmol)) in toluene (50 mL) was added
acetic anhydride (123 mg, 1.20 mmol), and the mixture was stirred for 1 h
at 80 °C. After the mixture was cooled, the solvent was removed by rotary
evaporation and the residue purified by FCC. The eluent was
dichloromethane/ethanol (5:1). Yield: 401 mg (91%) of 24 as white
crystals. Mp 299 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.74 (br t,
J =5 . 7H z ,2H ,N −H), 7.58 (d, J = 8.6 Hz, 1 H, 5-H), 7.32 (d, J =8 . 6H z ,
1 H, 6-H), 4.45 (s, 3 H, N−CH3), 3.47 (ddd, J = 13 Hz, 7.0 Hz, 5.7 Hz, 1
H, CH2), 3.12 (br t, J = 7.0 Hz, 1 H, 4-H), 2.97 (ddd, J =1 3H z ,7 . 0H z ,
5.7 Hz, 1 H, CH2), 1.62 (s, 3 H, CO−CH3), 1.34 (s, 3 H, 3-CH3), 1.17 (s,
3H ,3 - C H 3); MS EI m/z (relative intensity, %) 371 [M+￿ +4 ]( 1 ) ,3 6 9
[M+￿ + 2] (7), 367 [M+￿] (11), 308 (64), 295 (100), 281 (38), 260 (33).
Anal. (C17H19Cl2N3O2)C ,H ,N .
Biochemical Assays. Protein Purification. PIM1 was purified as
described previously.
20
DAPK3 (coding for residues V9 to G288) was cloned into the T7
expression vector pNIC28-Bsa4 and expressed as a TEV (tobacco etch
virus protease) cleavable N-terminal His6 fusion protein in the phage
resistant strain BL21 (DE3) R3 co-transformed with a chloramphenicol
resistant coexpression plasmid (pCOEX) expressing λ-phosphatase. An
amount of 1 mL of an overnight culture was used to inoculate 2 L of
TB medium containing 50 μg/mL kanamycin and 40 μg/mL chloram-
phenicol. E. coli cells were grown in 2.5 L baffled flasks at 37 °Cu n t i l
OD600 reached 2.0. The cultures were cooled to 25 °C, and expression of
DAPK3 was induced by adding 0.5 mM IPTG at an OD600 of 2.2. Cells were
resuspended in lysis buffer (50 mM HEPES buffer, pH 7.5, 500 mM NaCl,
5% glycerol) and lysed by sonication. Nucleic acids and cell debris were
removed by centrifugation. The cell lysate was loaded onto a Ni affinity,
HisTrap, 5 mL column (GE/Amersham Biosciences) equilibrated in lysis
buffer. The column was washed using 10 column volumes of 50 mM
HEPES buffer, pH 7.5, 500 mM NaCl, 20 mM imidazole, and 5% glycerol,
and DAPK3 was eluted using 50 mM HEPES buffer, pH 7.5, 500 mM
NaCl, 150 mM imidazole, and 5% glycerol. DTT was added to a final
concentration of 5 mM, and the His-tag was removed by the addition of
200 μg of TEV protease (14 h at 4 °C). The protein was loaded onto a
Hiload 16/60 Superdex 200 prep grade, 120 mL column (GE/Amersham
Bioscience) equilibrated in 50 mM HEPES, pH 7.5, 500 mM NaCl, 5%
glycerol, 5 mM DTT. After size exclusion chromatography the recombinant
protein was more than 95% pure as judged by SDS−PAGE, and ESI-MS
confirmed the correct mass of the protein. DAPK3 was concentrated to
12.6 mg/mL for crystallization studies.
Crystallization. Aliquots of the purified proteins were set up for
crystallization using a mosquito crystallization robot (TTP Labtech,
Royston U.K.). Coarse screens were typically set up onto Greiner
three-well plates using three different drop ratios of precipitant to
protein per condition (100 + 50 nL, 75 + 75 nL, and 50 + 100 nL).
Initial hits were optimized further using Greiner three-well plates and
scaling up the drop sizes in steps. Crystallizations were carried
out using the sitting drop vapor diffusion method at 4 °C. PIM1
(6 mg/mL) was concentrated in the presence of 17 μM β-carboline (17
or 20)a n d1 7μM consensus peptide (ARKRRRHPSGPPTA-amide).
Crystals with 17 were grown at 4 °C in 1.0 μL sitting drops, mixing
0.75 μL of the solution with 0.25 μL of a reservoir solution containing
0.14 M sodium malonate, 0.07 M Bis-Tris propane, pH 7.5, 14% PEG
3350, 7% ethylene glycol. Crystals of PIM1 with 20 were grown at
4 °C in 1.0 μL sitting drops, mixing 0.8 μL of protein solution with
0.2 μL of a reservoir solution containing 0.56 M sodium succinate, pH
7.0. Crystals of DAPK3 in complex with 20 were grown by mixing
50 μL of the protein (12.6 mg/mL in the presence of 1 mM 20)w i t h
100 μL of reservoir solution containing 0.1 M SPG, pH 6.0, 30.0% PEG 1K.
Data Collection and Structure Solution. Crystals were directly
flash frozen in liquid nitrogen in the case of the DAPK3 complex or were
supplemented by 20% ethylene glycol (in the case of the PIM1 complexes)
and flash frozen. Data were collected on an FR-E Superbright source using
an RAXIS IV plate detector at 1.542 Å (PIM1A/20)o ra tt h eS w i s s
L i g h tS o u r c eb e a m l i n eP X 1 0a t0 . 9 7 9 1 2Å( P I M 1 A / 17) or 0.9807 Å
(DAPK3/20). Indexing and integration were carried out using HKL-
2000
42 or MOSFLM,
43 and scaling was performed with SCALEPACK
42
or SCALA.
44 Initial phases were calculated by molecular replacement with
PHASER
45 using the known models of PIM1
41 and DAP.
46 Initial models
were built by ARP/wARP,
47 and building was completed manually with
COOT.
48 Refinement was carried out in REFMAC5.
49 Thermal motions
were analyzed using TLSMD,
50 and hydrogen atoms were included in late
refinement cycles. Data collection and refinement statistics can be found in
Table S2 (Supporting Information). The models and structure factors have
been deposited with PDB accession codes 3CXW (PIM1/17), 3CY2
(PIM1/20), and 3BHY (DAPK3/17).
Cell Based Assays. Cell Culture and Treatment with PIM
Inhibitor. Human leukemia cell lines MV4;11, RS4;11, MOLM13, SEM,
and K562 were purchased from DSMZ and maintained in RPMI 1640
with 10% FCS and 1% penicillin/streptomycin at 37 °Ci n5 %C O 2.T o
evaluate the effect on the cell proliferation, 20 (0−10 μM) was added to
the culture medium and the cultures were incubated for 48 h. Cell
proliferation and viability were assayed using cell proliferation reagent
WST-1 from Roche Diagnostics according to the manufacturer’s
instructions. Cell survival was calculated as a percentage normalized to
control cultures, and IC50 values were calculated using GraphPad Prism.
Protein Extraction and Western Blotting. MV4;11 cells were
grown at 5 × 105/mL, treated with 20 at 0−10 μM for various times,
harvested, and rinsed with ice-cold PBS. Ice-cold lysis buffer [10 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.5 mM EDTA,
10% glycerol, 10 mM NaF, 1 mM Na3VO4, protease inhibitor cocktail]
was added to the cells, and the mixture was incubated for 20 min on
ice followed by 15 min of centrifugation at 12000g. Cleared lysates
were assayed for protein concentration using the Bradford protein
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to 15% SDS−PAGE and transferred onto a PVDF membrane.
Membranes were blotted with primary antibodies (diluted according
to the manufacturer’s recommendations), followed by horseradish
peroxidase-conjugated secondary antibodies, and the proteins were
detected by SuperSignal West Femto maximum sensitivity substrate
(Pierce). The same blots were stripped and reprobed with desired
antibodies to confirm equal loading with the following antibodies: anti-
phospho-4E-BP1, anti-4E-BP1 (Cell Signaling Technology), and anti-
β-actin (Sigma).
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